1. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis

   • Giulia Ronconi
   • Letizia Dondi
   • Nello Martini

   Original Research Article 25 May 2021 Pages: 595 - 604

   

2. Prehospital Adenosine Diphosphate Receptor Blocker Use, Culprit Artery Flow, and Mortality in STEMI: The MADDEC Study

   • Markus Hautamäki
   • Leo-Pekka Lyytikäinen
   • Jussi Hernesniemi

   Original Research Article Open access 08 June 2021 Pages: 605 - 613

   

3. Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database

   • Keiko Ogawa
   • Yoshihiro Kozuka
   • Rumiko Hosoki

   Original Research Article 10 June 2021 Pages: 615 - 627

   

4. A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV

   • Randolph P. Matthews
   • Deanne Jackson Rudd
   • Marian Iwamoto

   Original Research Article Open access 21 June 2021 Pages: 629 - 638

   

5. Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects

   • Ashit Trivedi
   • Mia Mackowski
   • Edward Lee

   Original Research Article 10 June 2021 Pages: 639 - 645

   

6. Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects

   • Ashit Trivedi
   • Rajneet K. Oberoi
   • Edward Lee

   Short Communication 07 June 2021 Pages: 647 - 652

   

7. Successful Intravenous Thrombolysis and Endovascular Treatment for Acute Ischemic Stroke in a Patient Pretreated with Ticagrelor: A Case Report and Literature Review

   • Federica Rizzo
   • Domenico Maria Mezzapesa
   • Marco Petruzzellis

   Research Letter 09 June 2021 Pages: 653 - 657

   

8. Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’

   • Andrew Koren
   • Andreas Karas
   • Roger Echols

   Letter to the Editor Open access 26 May 2021 Pages: 659 - 660

9. Response to “Comment on: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety”

   • Young R. Lee

   Letter to the Editor 10 June 2021 Pages: 661 - 662

10. Blister-Packing of 2 mg Buprenorphine Monoproduct as a Patient-Centered Method of Microdosing for Buprenorphine Induction

    • Anthony J. Accurso

    Letter to the Editor 14 June 2021 Pages: 663 - 664

11. Buprenorphine Microinduction: Logistical Barriers and the Need for Convergent Evidence

    • Joao P. De Aquino
    • Suprit Parida
    • Mehmet Sofuoglu

    Letter to the Editor 09 June 2021 Pages: 665 - 665